Security key
68232V884
Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW)
CUSIP: 68232V884
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common Stock, par value $0.01 per share
- Total 13F shares
- 646,356
- Total 13F value
- $3,800,574
- Share change
- +636,400
- SEC-reported price per share
- $5.88
- Number of holders
- 10
- Value change
- +$3,742,033
- Number of buys
- 9
- Shares outstanding
- 16,062,541
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
10
Top holders
10
TRAW full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2024
Traws Pharma, Inc. SEC filings
Traws Pharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 68232V884
Recent filing periods:
Ownership snapshot
Top reported holders of TRAW - Traws Pharma, Inc. - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Viriom, Inc.
Disclosed value leader
Viriom, Inc.
Comparable rows
0/15
Latest evidence
30 Jun 2024
3/4/5
13F
Highest disclosed value: $1,480,590
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Viriom, Inc. has the largest disclosed position value at $1.48M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Viriom, Inc.'s linked filing trail.
Disclosed position value
Top 5
Viriom, Inc.
$1.48M
ORBIMED ADVISORS LLC
$466.9K
VANGUARD GROUP INC
$315.8K
BlackRock Finance, Inc.
$111.2K
GEODE CAPITAL MANAGEMENT, LLC
$100.1K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Viriom, Inc. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$1,480,590
1,645,100 shares
|
— | 03 Apr 2024 |
| ORBIMED ADVISORS LLC |
13F
Company
|
—
class O/S missing
|
$466,918
1,045,261 shares
|
— | 30 Jun 2024 |
| VANGUARD GROUP INC |
13F
Company
|
—
class O/S missing
|
$315,782
706,921 shares
|
— | 30 Jun 2024 |
| BlackRock Finance, Inc. |
13F
Company
|
—
class O/S missing
|
$111,174
248,878 shares
|
— | 30 Jun 2024 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
class O/S missing
|
$100,115
224,086 shares
|
— | 30 Jun 2024 |
| Steven M. Fruchtman |
3/4/5
PRESIDENT, CHIEF EXECUTIVE OFF, Director
|
—
mixed-class rows
|
$98,282
121,014 shares
mixed-class rows
|
— | 13 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
10
Shares
646,356
Rows available
10
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q4 2025 Across Filers
Q4 2025 holders
21
Q3 2024 holders
10
Holder diff
-11
| Investor | Q4 2025 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q4 2025 value | Q3 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend